Mirati Therapeutics Inc (MRTX) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket
 
Mirati Therapeutics Inc   (NASDAQ: MRTX)
 

Mirati Therapeutics Inc Growth Comparisons

Select each growth Category to receive further Information





MRTX Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q3 MRQ) 201.97 % -4.57 % -0.57 % -0.67 %
Q / Q Revenue Growth (Q3 MRQ) 19.8 % -0.36 % 0.55 % -1.14 %
Y / Y Revenue Growth (for 12 months ending Q3 TTM) 223.63 % -5.42 % -2.85 % %
Sequential Revenue Growth (for 12 months ending Q3 TTM) 40.29 % -1.23 % -0.19 % 0.04 %
Revenue 5 Year Average Growth - 10.99 % 8.94 % 9.55 %


MRTX's Growth Comparisons in III. Quarter 2023




Despite the -4.57% decline in the Major Pharmaceutical Preparations industry, Mirati Therapeutics Inc showed impressive surge in Revenue in the third quarter 2023 by 201.97% from the same quarter a year ago, to 16 millions, Healthcare sector decreased -0.57%. Although Major Pharmaceutical Preparations industry's Sales were softer then -0.67% overall market growth, Mirati Therapeutics Inc and the Healthcare sector have delivered above average market Sales.

Top-line improved by 19.8% from the second quarter. Looking into annual sales rise of %, and S & P 500's average yearly sales growth is 9.55% over the five years, including only Businesses with the third quarter 2023 Results. Mirati Therapeutics Inc grew less than the market.


Growth Rates of MRTX's Income in the third quarter 2023


MRTX Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q3 MRQ) - -51.35 % -43.07 % 0.53 %
Sequential Operating Income Change (Q3 MRQ) - 34.98 % 33.59 % 7.86 %
Y / Y Operating Income Growth (Q3 TTM) - -26.93 % -25.69 % -9.48 %
Sequential Operating Income Growth (Q3 TTM) - -14.2 % -11.71 % -0.31 %
Operating Income 5 Year Avg. Change - 15.5 % 4.67 % 8.71 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q3 MRQ) - -72.53 % -80.3 % 1.33 %
Sequential Income from Cont. Ops. Change (Q3 MRQ) - 65.43 % 274.93 % 11.41 %
Y / Y Income from Cont. Ops. Change (Q3 TTM) - -58.66 % -54.07 % -9.41 %
Sequential Income from Cont. Ops. Change (Q3 TTM) - -30.54 % -29.11 % 0.17 %
Income from Cont. Ops. 5 Year Avg. Change - 16.52 % 8.32 % 11.88 %

MRTX Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q3 MRQ) - 22.25 % 3.05 % 6.99 %
Q / Q Net Income Growth (Q3 MRQ) - 683.38 % 2068.54 % 15.58 %
Y / Y Net Income Change (Q3 TTM) - -33.36 % -32.19 % -7.15 %
Sequential Net Income Change (Q3 TTM) - 10.16 % 2.42 % 1.71 %
Net Income 5 Year Avg. Growth - 21.26 % 10.49 % 3.58 %

MRTX's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q3 MRQ) - -72.69 % -80.3 % 1.33 %
Sequential EPS from Cont. Ops. Change (Q3 MRQ) - 246.36 % 274.93 % 11.41 %
Y / Y EPS from Cont. Ops. Change (Q3 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q3 TTM) - - - 117.26 %
EPS from Cont. Ops. 5 Year Avg. Growth - 4.93 % 8.32 % 11.88 %



MRTX EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q3 MRQ) - 21.55 % 3.05 % 11.88 %
Q / Q EPS Net Growth (Q3 MRQ) - 1540.14 % 2068.54 % 15.58 %
Y / Y EPS Net Change (for 12 months ending Q3 TTM) - - - 60266.88 %
Sequential EPS Net Change (for 12 months ending Q3 TTM) - - - 115.79 %
EPS Net 5 Year Avg. Change - 21.26 % 10.49 % 3.58 %



Mirati Therapeutics Inc reported bottom-line of $ -2.49 in the third quarter, compare to $ -3.09 in the same quarter a year ago. Major Pharmaceutical Preparations industry grew by 21.55%, while Healthcare sector increased by 3.05%, and overall market improved by 6.99%.

The bottom-line improved by 19.8% from the second quarter. Looking into annual income per share rise of %, and S & P 500's average yearly income per share growth is 3.58% over the five years, including only Businesses with the third quarter 2023 earnings reports. Mirati Therapeutics Inc grew less than the market.

MRTX Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q3 MRQ) - 6.55 % -3.77 % 25.44 %
Sequential Free Cash Flow Change (Q3 MRQ) - 152.51 % 64.54 % 29.02 %
Y / Y Free Cash Flow Change (Q3 TTM) - -19.71 % -18.36 % -3.19 %
Sequential Free Cash Flow Change (Q3 TTM) - 4.85 % 3.08 % 11.89 %
Free Cash Flow 5 Year Avg. Change - 8.35 % 6.34 % -24.89 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q3 MRQ) 287.63 % 22.37 % 38.63 % -
Sequential Net Cash Flow Change (Q3 MRQ) - - - -
Y / Y Net Cash Flow Change (Q3 TTM) - - - -
Sequential Net Cash Flow Change (Q3 TTM) - - 11.14 % -
Net Cash Flow 5 Year Avg. Change - - -32.87 % 34.23 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q3 MRQ) -97.1 % 1.5 % 3.25 % 69.59 %
Sequential Capital Expenditures Change (Q3 MRQ) -95.01 % 6.34 % 5.53 % 16.4 %
Y / Y Capital Expenditures Change (Q3 TTM) -72.54 % 9.14 % 5.6 % -8.48 %
Sequential Capital Expenditures Change (Q3 TTM) -39.59 % 0.2 % 0.92 % 18.81 %
Capital Expenditures 5 Year Avg. Change 126.71 % 13.36 % 9.54 % 8.63 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 







Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.